Health

American Cancer Society urges routine prostate cancer screening for men starting at 50

Updated guidelines recommend biennial blood tests for average-risk men ages 50 to 69, marking a major shift from previous advice that left screening to individual decision-making.

Healthcare Stock Photo
[www.patientcaretechniciansalary.net/ Michael Havens -] / Wikimedia Commons, CC BY 2.0

The American Cancer Society updated its guidance on Thursday, Nov. 12, recommending that men at average risk for prostate cancer undergo screening with a prostate-specific antigen blood test every two years from ages 50 to 69.

Under the revised standards published in CA: A Cancer Journal for Clinicians, groups at higher risk—including Black men and individuals with a strong family history of the disease—should begin annual screening at age 45. Men between ages 70 and 74 are advised to consult with their physicians to determine if testing aligns with their overall health and life expectancy, according to the organization.

The updated advice represents a significant shift from guidelines established in 2010, which advised doctors and patients to engage in shared decision-making to weigh the benefits and risks of testing. Medical experts noted that leaving the choice flexible meant many men were never offered the test.

Stronger evidence and rising advanced cases

The change comes as public health leaders confront a rise in late-stage prostate cancer diagnoses. An American Cancer Society study revealed that prostate cancer diagnoses grew by about three percent annually from 2014 to 2021, while advanced metastatic cases increased by roughly six percent each year among men 55 and older, NBC News reported.

Prostate cancer is the second leading cause of cancer death among U.S. men, behind lung cancer, with more than 36,000 deaths expected this year, according to the New York Post and NBC News. While early-stage prostate cancer has a five-year survival rate exceeding 99 percent, only about a third of men diagnosed with late-stage disease survive five years, CNN reported.

Dr. William L. Dahut, chief scientific officer of the American Cancer Society, stated that long-term research from Europe helped prompt the update. That data demonstrated that biennial PSA screening among middle-aged men led to a 13 percent reduction in prostate cancer mortality, CNN reported.

“PSA testing remains the cornerstone of detecting prostate cancer early, and we now have stronger evidence of its benefits,” Dr. Robert Smith said in an American Cancer Society statement reported by the New York Post.

Balancing benefits against potential harms

Prostate-specific antigen, or PSA, is a protein manufactured by the prostate gland. Elevated blood levels can signal cancer, though high readings can also stem from inflammation or a noncancerous enlarged prostate. For decades, routine screening remained controversial because many prostate tumors grow slowly and may never cause harm during a patient’s lifetime.

Past concerns over false positives, unnecessary biopsies, and invasive treatments that caused side effects such as urinary incontinence and sexual dysfunction prompted some health panels to limit screening. In 2012, the U.S. Preventive Services Task Force recommended against PSA testing for men of all ages. However, screening rates subsequently dropped, and late-stage diagnoses began rising across the nation, NBC News reported.

Medical experts emphasize that modern diagnostic tools have significantly reduced the risks associated with screening. Following an elevated PSA reading, doctors now frequently utilize repeat tests, magnetic resonance imaging scans, and specialized biomarker tests to evaluate whether a biopsy is necessary, CNN and the New York Post reported. Patients diagnosed with low-risk cancers are increasingly offered active surveillance rather than immediate surgery or radiation.

The updated guidance also highlights the ongoing debate surrounding health insurance coverage. While Medicare and many private insurance plans cover initial PSA blood tests, follow-up diagnostic procedures such as MRIs and biopsies frequently involve out-of-pocket costs, according to experts cited by CNN.